NN2211-8841 Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS1000001037
• Study ID:
  1000001037
• Official title and acronym:
  NN2211-8841 Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Novo Nordisk

Study timelines

Date when funding contract was signed

Planned:31/03/2023

Actual:31/03/2023

Study start date

Planned:31/12/2025

Actual:31/12/2025

Date of final study report

Planned:31/03/2027

Sources of funding

Pharmaceutical company and other private sector 

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable